Journal
DIABETES & METABOLISM
Volume 42, Issue 5, Pages 358-363Publisher
MASSON EDITEUR
DOI: 10.1016/j.diabet.2016.04.005
Keywords
Exenatide; FGF21; Insulin resistance; Type 2 diabetes
Categories
Funding
- Major National Basic Research Program of P.R. China [2011CB503904]
- Chinese National Natural Science Foundation [81270369, 81070244, 30770873]
- Beijing Natural Science Foundation [7142060]
- Capital Clinical Research Foundation of Beijing Municipal Commission of Science and Technology [Z131107002213024]
- foundation of Beijing Key Laboratory of Metabolic Disturbance-Related Cardiovascular Disease and Beijing Municipal Administration of Hospitals' Youth Programme [QML20150308]
Ask authors/readers for more resources
Aim. - Fibroblast growth factor 21 (FGF21) has been demonstrated to be a metabolic regulator with beneficial effects. Several studies have shown that type 2 diabetes mellitus (T2DM) patients have increased FGF21 levels and decreased expression of FGF receptors, suggesting a state of 'FGF21 resistance'. The aim of this study was to investigate the effects of the glucagon-like peptide (GLP)-1 receptor agonist exenatide on FGF21 levels and other metabolic parameters in patients with newly diagnosed T2DM. Methods. - A total of 100 participants, comprising 47 newly diagnosed T2DM patients and 53 age-matched healthy controls, were recruited. T2DM patients were assigned to 12 weeks of exenatide treatment. Their FGF21 levels and other metabolic parameters were measured before and after exenatide treatment. Results. - T2DM patients had significantly higher FGF21 levels than the controls. No difference in FGF21 was found between overweight and non-overweight control subgroups. In T2DM patients, exenatide treatment resulted in decreases in BMI, HbA(1c), total cholesterol and triglycerides, and also in FGF21 (149.17 +/- 81.36 vs 102.17 +/- 64.12 ng/mL; P < 0.01). Homoeostasis model assessment for insulin resistance (HOMA-IR) was also decreased [3.02 (2.10-4.63) vs 2.56 (1.80-4.13); P <0.05] while homoeostasis model assessment for beta-cell function (HOMA-B) was significantly higher after treatment [32.30 (17.82-59.42) vs 72.56 (46.63-99.58); P < 0.05]. The change in FGF21 (Delta FGF21) was negatively correlated with changes in fasting insulin (Delta insulin, r = -0.306; P < 0.05) and C-peptide (Delta C-peptide, r= -0.319; P < 0.05) levels. Conclusion. - Besides the improvement in insulin resistance and recovery of beta-cell function, 12 weeks of exenatide treatment may also play a role in lowering FGF21 levels in T2DM patients. (C) 2016 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available